JUNS

Jupiter Neurosciences Inc

Apr 02 • 04:00PM ET

0.3687

-0.0110 -2.90 %

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-0.26	Insider Own	57.36%	Shs Outstand	34.45M	Perf Week	5.64%
Market Cap	13.38M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	15.47M	Perf Month	-18.61%
Enterprise Value	14.91M	PEG	-	EPS next Q	-	Inst Own	4.67%	Short Float	0.51%	Perf Quarter	-63.85%
Income	-8.64M	P/S	669.00	EPS this Y	-	Inst Trans	9.01%	Short Ratio	0.25	Perf Half Y	-78.31%
Sales	0.02M	P/B	-	EPS next Y	-	ROA	-146.94%	Short Interest	0.08M	Perf YTD	-63.85%
Book/sh	-0.05	P/C	3.53	EPS next 5Y	-	ROE	-738.83%	52W High	3.33 -88.93%	Perf Year	-42.30%
Cash/sh	0.10	P/FCF	-	EPS past 3/5Y	-18.29% -7.78%	ROIC	-	52W Low	0.31 20.43%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	80.59%	Volatility	17.11% 14.81%	Perf 5Y	-
Dividend TTM	-	EV/Sales	745.50	EPS Y/Y TTM	-247.35%	Oper. Margin	-40873.19%	ATR (14)	0.05	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.63	Sales Y/Y TTM	-	Profit Margin	-39662.77%	RSI (14)	39.80	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.65	EPS Q/Q	-62.26%	SMA20	-3.89%	Beta	2.78	Target Price	25.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-28.23%	Rel Volume	0.13	Prev Close	0.38
Employees	5	LT Debt/Eq	-	Earnings	Dec 03	SMA200	-67.99%	Avg Volume	317.90K	Price	0.37
IPO	Dec 03, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	42,229	Change	-2.90%

Mar-31-26 12:00PM	Jupiter Neurosciences to Present at Emerging Growth Conference on April 2 (GlobeNewswire) +15.83%
Mar-02-26 08:00AM	Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026 (GlobeNewswire)
Feb-25-26 08:30AM	Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago (GlobeNewswire)
Feb-23-26 09:30AM	Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution (GlobeNewswire)
Feb-12-26 01:07PM	Jupiter Neurosciences Selected as B2i Digital Featured Company (NewMediaWire) -5.08%
06:00AM	Loading…
Jan-28-26 06:00AM	Jupiter Neurosciences Expands Nugevia Addressable Market with Focus on GLP-1 Users (GlobeNewswire) -23.53%
Jan-27-26 10:45AM	Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference (ACCESSWIRE)
Dec-23-25 08:00AM	Join Jupiter Neurosciences' Exclusive Live Investor Webinar and Q&A Session on January 6 (GlobeNewswire)
Dec-10-25 02:29PM	$50B+ Longevity Opportunity: Jupiter Neurosciences CEO Christer Rosen & President Alison Silva, Live at Nasdaq (Exec Edge)
Dec-03-25 08:00AM	Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum (GlobeNewswire)
Dec-02-25 04:15PM	Jupiter Neurosciences to Participate in NobleCon21 (Newsfile)
Nov-05-25 08:30AM	Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL in Parkinson's Disease (GlobeNewswire) +8.80%
Oct-27-25 08:30AM	Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing (GlobeNewswire) +11.11%
Sep-15-25 08:00AM	Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia Brand Ambassador (GlobeNewswire) +5.26%
Aug-26-25 08:00AM	Jupiter Neurosciences Launches Nugevia Website and Opens Pre-Orders for Groundbreaking Longevity Supplements (GlobeNewswire)
08:12AM	Loading…
Aug-19-25 08:12AM	Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia Brand Ambassador (GlobeNewswire)
Aug-11-25 08:00AM	Jupiter Neurosciences Introduces Nugevia MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience (GlobeNewswire)
Jul-23-25 08:00AM	Jupiter Neurosciences Highlights Critical Advancement of JOTROL Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science (GlobeNewswire)
Jul-10-25 04:05PM	Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +18.63% +19.90%
Jun-30-25 03:15PM	Jupiter Neurosciences Showcases Nugevia PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery (GlobeNewswire)
Jun-27-25 08:00AM	Jupiter Neurosciences Unveils Nugevia GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science (GlobeNewswire)
Jun-23-25 08:00AM	Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia Brand Ambassador (GlobeNewswire) +8.11%
08:00AM	Jupiter Neurosciences Names Golf Legend Annika Sorenstam as First Nugevia Brand Ambassador (GlobeNewswire)
Jun-09-25 07:00AM	Jupiter Neurosciences Launches Nugevia: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science (GlobeNewswire) +15.20%
Apr-08-25 08:00AM	Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter (GlobeNewswire)
Mar-07-25 10:10AM	Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire)
Mar-04-25 08:00AM	Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products (GlobeNewswire) +6.14%
Feb-04-25 09:25AM	Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones (GlobeNewswire) +11.36%
Feb-03-25 08:00AM	Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial (GlobeNewswire) -5.84%
Jan-30-25 08:00AM	Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial (GlobeNewswire) -8.20%
08:00AM	Loading…
Jan-13-25 08:00AM	Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL Trials (GlobeNewswire)
Dec-04-24 04:56PM	Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering (GlobeNewswire) +9.93%
Dec-02-24 07:00PM	Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq (GlobeNewswire)

Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The firm offers JOTROL, an enhanced orally administered resveratrol formulation, designed to deliver therapeutically relevant, safe levels of resveratrol. The company was founded by Christer Rosen, Alexander Rosen, Claes Wahlestedt, Marshall Hayward, and Shaun P. Brothers in January 2016 and is headquartered in Jupiter, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Elmasri Saleem	CFO and Secretary	Jun 02 '25	Option Exercise	0.00	66,293	0	66,239	Jul 07 09:28 PM
Silva Alison D.	Pres + Chief Business Officer	Jul 01 '25	Buy	1.03	750	772	112,777	Jul 03 08:56 PM
ROSEN CHRISTER	CEO and Chairman	Jul 01 '25	Buy	1.02	3,600	3,667	11,078,892	Jul 03 02:53 PM
Silva Alison D.	Pres + Chief Business Officer	Jun 02 '25	Option Exercise	0.00	110,227	0	110,227	Jul 01 07:55 PM
Silva Alison D.	Pres + Chief Business Officer	Jun 30 '25	Buy	1.03	950	978	112,027	Jul 01 07:55 PM
Silva Alison D.	Pres + Chief Business Officer	Jun 27 '25	Buy	1.03	850	877	111,077	Jul 01 07:55 PM
ROSEN CHRISTER	CEO and Chairman	Jun 02 '25	Option Exercise	0.00	973,466	0	11,067,476	Jul 01 07:55 PM
ROSEN CHRISTER	CEO and Chairman	Jun 30 '25	Buy	1.02	7,650	7,810	11,075,292	Jul 01 07:55 PM
ROSEN CHRISTER	CEO and Chairman	Jun 27 '25	Buy	1.06	166	176	11,067,642	Jul 01 07:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JUNS

Jupiter Neurosciences Inc

Upgrade your Finviz experience